Orchid Pharma Limited reported its audited financial results for the quarter and financial year ended March 31, 2026. The company achieved a standalone net profit of ₹4,520.79 lakhs for the year. Key strategic highlights include the successful 100% acquisition of Allecra Therapeutics’ global assets, ensuring full repatriation of the antibiotic Enmetazobactam to India, and progress on the proposed amalgamation of Dhanuka Laboratories Limited into the company.
Financial Performance Overview
For the financial year ended March 31, 2026, Orchid Pharma Limited recorded a total standalone income of ₹86,656.92 lakhs. The standalone net profit for the year stood at ₹4,520.79 lakhs, compared to ₹10,648.34 lakhs in the previous year. On a consolidated basis, the total income for the year was ₹84,650.06 lakhs, with a net profit of ₹2,054.70 lakhs.
Strategic Acquisitions and Developments
The company has achieved a significant milestone by consolidating its global intellectual property. It completed the 100% acquisition of assets from Allecra Therapeutics GmbH (Germany) and Allecra Therapeutics SAS (France). This strategic move gives Orchid Pharma full global ownership of the novel antibiotic Enmetazobactam (branded as EXBLIFEP), marking a major repatriation of Indian-discovered medical innovation.
Corporate Restructuring and Internal Governance
Orchid Pharma is currently undergoing a formal amalgamation process with its holding company, Dhanuka Laboratories Limited. The company has secured ‘No Objection’ certificates from stock exchanges, and the matter is currently awaiting the final order from the National Company Law Tribunal (NCLT) following a hearing on March 18, 2026.
Additionally, the Board of Directors has approved the appointment of M/s. T R Chadha & Co., LLP as the Internal Auditor for the upcoming financial year 2026-27, further strengthening the company’s internal audit and governance frameworks.
Capital Utilization
As of March 31, 2026, the company has successfully utilized ₹33,256 lakhs out of the ₹39,180 lakhs raised through its Qualified Institutional Placement (QIP) in June 2023. The funds were primarily directed toward the Jammu Manufacturing Facility, debt repayment, and capital expenditure for the Alathur API facility.
Source: BSE
